Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 6/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5393573 | 0.90 | METAP2 (0.52) | METAP2P2RX7ADORA2A | |
| SCHEMBL5376560 | 0.90 | TP53 (0.47) | METAP2GAAFLT3MKNK2MAPT | |
| SCHEMBL5385922 | 0.90 | GAA (0.49) | GAAFLT3MKNK2MAPTMEN1 | |
| SCHEMBL5372409 | 0.88 | METAP2 (0.50) | METAP2MAPTKMT2AP2RX7MAPK1 | |
| SCHEMBL5376731 | 0.85 | CYP2E1 (0.50) | METAP2GAAFLT3MKNK2MAPT | |
| SCHEMBL5376838 | 0.85 | METAP2 (0.67) | METAP2MAPTLMNAL3MBTL1HTT | |
| SCHEMBL5380596 | 0.84 | METAP2 (0.51) | METAP2GAAFLT3MKNK2MAPT | |
| SCHEMBL5397353 | 0.83 | KMT2A (0.49) | GAAMEN1KMT2ATSHR | |
| SCHEMBL5391914 | 0.82 | METAP2 (0.68) | METAP2GAAFLT3MAPK1 | |
| SCHEMBL5382003 | 0.81 | METAP2 (0.52) | METAP2GAAFLT3MKNK2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1223932-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-01-15 | — | — | EP | claimed |
| EP-1223932-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2002-07-24 | — | — | EP | claimed |
| WO-2001024796-A1 | 1,2,4-TRIAZOLE DERIVATIVES, COMPOSITION, PROCESS OF MAKING AND METHODS OF USE | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-12 | — | — | WO | claimed |
| US-7304082-B2 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050267185-A1 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | SMITHKLINE BEECHAM CORPORATION | 2005-12-01 | — | — | US | disclosed |
| EP-1223932-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-01-15 | — | — | EP | disclosed |
| EP-1223932-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001024796-A1 | 1,2,4-TRIAZOLE DERIVATIVES, COMPOSITION, PROCESS OF MAKING AND METHODS OF USE | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267185-A1 | 1,2,4-triazole derivatives, compositions, process of making and methods of use | METAP2, METAP1, DNPEP | METAP2 1/4885GAA 2089/4885FLT3 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.